Combining expertise to transform and accelerate drug discovery and development
No one business can revolutionise the way medicines are discovered and developed alone. We enable our partners to leverage the benefits and insights of the Benevolent Platform® to drive drug discovery innovation and generate novel treatments. We work across every stage of the drug discovery process from Target Identification, Molecular Design through to Clinical Development and Precision Medicine.
We are collaborating with AstraZeneca to identify novel drugs for Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD). The first novel AI-generated CKD target from the collaboration has now entered AstraZeneca’s portfolio.